Ausgewählte Vorträge

Michael Schlander; OECI Task Force:

The Socioeconomic Impact of Cancer. [Krebs und Armut]

Michael Schlander; OECI Task Force:

Krebs und Armut.

[11. Krebsaktionstag]

Michael Schlander, Ramon Schäfer, Lorenz Selberg:

Nutzen der Labormedizin in der Schweiz.

Alec Morton, Michael Schlander:

Debate - Value and Impact of HTA:
"Are Our Current Ways to Conduct HTAs Fit For Purpose?"

(Präsentation ist auf Anfrage erhältlich)

Michael Schlander, Jasper Ubels, Camila Quirland, Valesca Retel:

Panel Session - Theme:

Towards a broader patients' perspective: The theory and practice of socioeconomic impact research.

(Concurrent Breakout Session 4)

Anett Molnar, Manuel Störzel, Muchandi T. Muchadeyi, ..., Michael Schlander:

Health economic evaluations alongside new clinical trial designs – Results of an international expert panel workshop.

(Poster-Präsentation)
Value in Health, 2022; 25(12) Supplement, S354.

Muchandi T. Muchadeyi, Karla Hernandez-Villafuerte, Michael Schlander:

The nature of quality appraisal in systematic literature reviews of health state utility values (HSUVS). A rapid evidence review.

(Poster-Präsentation)
Value in Health, 2022; 25(12) Supplement, S429.

P. Duy Pham, Jasper Ubels, Karla Hernandez-Villafuerte, Rachel Eckford, Michael Schlander:

Developing a conceptual framework for socioeconomic impact research in European cancer patients: A best-fit framework synthesis.

(Poster-Präsentation)
Value in Health, 2022; 25(12) Supplement, S430.

C. Quirland, F. Maza, J. Fuentes, ..., M. Schlander:

Costing for Socioeconomic Impact Analysis: Implications of Adopting a Patient's Perspective.

(Poster-Präsentation)
Value in Health, 2022; 25(12) Supplement, S67..

Jana Schneider, Diego Hernandez, CAESAR Study Group, Volker Arndt, Michael Schlander:

To what extent are long-term breast cancer survivors subjected to financial burden in Germany? Results from a patient survey-based study.

(Poster-Präsentation)
Value in Health, 2022; 25(12) Supplement, S397.

Manuel Störzel, Anett Molnar, Michael Schlander:

Challenges of health economic evaluations alongside innovative clinical trial designs in precision oncology – Results of a literature review.

(Poster-Präsentation)
Value in Health, 2022; 25(12) Supplement, S154.

Ramon Schaefer, Diego Hernandez, Michael Schlander:

"Cancer-related HTAs in England and Germany: A comparison of outcomes and evaluation criteria"

(Präsentation ist auf Anfrage erhältlich)

Rachel Eckford, Andrea Gaisser, Evelyn Kludt, Susanne Weg-Remers, Michael Schlander:

"Financial impact on cancer patients in Germany during the COVID-19 pandemic"

(Präsentation ist auf Anfrage erhältlich)

Michael Schlander:

"The Cost of New Drug Development"

(Präsentation ist auf Anfrage erhältlich)

Andrea Gaisser, Rachel Eckford, Evelyn Kludt, Michael Baumann, Susanne Weg-Remers, Michael Schlander:

"Auswirkungen der Corona-Pandemie für Krebsbetroffene und ihre Versorgung: Ergebnisse einer Befragungsstudie"

(Online Poster-Präsentation ist auf Anfrage erhätlich)

Andrea Gaisser, Rachel Eckford, Michael Baumann, Evelyn Kludt, Susanne Weg-Remers, Michael Schlander:

Impact of the corona pandemic on cancer patients: Results from a German cross-sectional pilot study.

(Poster-Präsentation ist auf Anfrage erhältlich)

Rachel Eckford, Andrea Gaisser, Volker Arndt, Michael Baumann, Evelyn Kludt, Katja Mehlis, Jasper Ubels, Eva Winkler, Susanne Weg-Remers, Michael Schlander:

Online survey of cancer patients on changes in care and on psycho-social burden during the pandemic.

(Poster-Präsentation ist auf Anfrage erhältlich)

Jeff Richardson, Marteen Postma, Soren Holm, Michael Schlander:

Social Cost Value Analysis: Do we need an alternative health economic evaluation paradigm?

(Online-Panel)
Konferenzband / Virtual ISPOR Europe 2020.

Michael Schlander, Tao Ran, Patrick Schmidt, Stefan Eichmüller:

The acquisition cost and efficiency of CAR T-cell therapies: can they be improved by decentralized manufacturing?

(Online Poster-Präsentation)
Value in Health (2020), 23(S2): S460.

Ramon Schaefer, Diego Hernandez, Michael Schlander:

The role of the budget impact: A multivariate analysis of health technology assessment (HTA) outcomes by GBA/IQWiG in Germany and NICE in England.

(Online Poster-Präsentation)
Value in Health (2020), 23(S2): S530.

Karla Hernandez-Villafuerte, Michael Schlander, Chih-Yuan Cheng, Jorge Mestre-Ferrandiz, Michael Baumann:

How much does it cost to research & develop a new drug? A systematic review and evaluation of 40 years of literature.

(Online Poster-Präsentation)
Value in Health (2020), 23(S2): S756.

Rachel Eckford, Karla Hernandez-Villafuerte, Leander Hirschberg, Michael Schlander:

A systematic review of the socioeconomic impact of cancer on patients and families: Are differences among countries being effectively captured and addressed?

(Online Poster-Präsentation)
Value in Health (2020), 23(S2): S478.

Chih-Yuan Cheng, Silvia Calderazzo, C Schramm, Michael Schlander:

Modeling the duration of protective effects and resource use of colonoscopy screening by a discrete event simulation model calibrated with German screening registry data.

(Online Poster-Präsentation)
Value in Health (2020), 23(S2): S456-457.

Anett Molnar, Titus Brinker, Tanja Jutzki, Karla Hernandez-Villafuerte, Michael Schlander:

Direct and indirect cost of malignant cutaneous melanoma in European countries – Results of a literature review.

(Abstract Video-Präsentation)
DGHO Jahrestreffen 2020.

Michael Schlander, Tao Ran, Patrick Schmidt, Stefan Eichmüller:

Can we reduce the acquisition cost of CAR T-cell therapies?

(Online Poster-Präsentation)
Annals of Oncology (2020), 31(S4): S966.

Ramon Schaefer, Diego Hernandez, Michael Schlander:

Health technology assessment (HTA) in England, France and Germany: What do we know about variations in cancer-related HTA outcomes?

(Online-Präsentation)
Annals of Oncology (2020), 31(S4): S1197.

Karla Hernandez-Villafuerte, Michael Schlander, Chih-Yuan Cheng, Jorge Mestre-Ferrandiz, Michael Baumann:

How much does it cost to research and develop a new medicine? A systematic review and evaluation of 40 years of literature.

(Online Poster-Präsentation)
Annals of Oncology (2020), 31(S4): S962.

Chih-Yuan Cheng, Silvia Calderazzo, C Schramm, Michael Schlander:

Modelling the long-term effectiveness of colonoscopy screening by a discrete event simulation model calibrated with German screening registry data.

(Online Poster-Präsentation)
Annals of Oncology (2020), 31(S4): S457-S458.

Ramon Schaefer, Diego Hernandez, Michael Schlander:

´Advancing evidence to action´: A comparison of health technology assessment (HTA) outcomes in England, France and Germany.

(Online Poster-Präsentation)
Value in Health (2020), 23(S1): S70.

Diego Hernandez, Michael Schlander:

Income loss after a cancer diagnosis in Germany: an analysis based upon the socio-economic panel survey.

(Online Poster-Präsentation)
Value in Health (2020), 23(S1): S76.

Rachel Eckford, Karla Hernandez-Villafuerte, Leander Hirschberg, Michael Schlander:

The social and socioeconomic impact ofcancer on patients and their families: A systematic review.

(Online Poster-Präsentation)
Value in Health (2020), 23(S1): S78.